Teprotumumab BLA Submitted for Active Thyroid Eye Disease
Teprotumumab is an investigational fully human monoclonal antibody that works by inhibiting the insulin-like growth factor 1 receptor.
Hyperthyroidism
Radioactive Iodine Treatment Linked to Solid Cancer Mortality in Hyperthyroidism
Greater organ-absorbed doses of radioactive iodine seem to be positively associated with risk for death from solid cancer in patients with hyperthyroidism.
High Free T4 Levels Within Reference Range Associated With Atrial Fibrillation
Higher levels of free T4 that remain within the reference range are associated with a greater prevalence and incidence of atrial fibrillation.
Autoimmune Thyroid Disease Associated With Onset of Rheumatoid Arthritis
Rheumatoid arthritis is associated with an increased occurrence of autoimmune thyroid disease, indicated by an increased risk of developing autoimmune thyroid disease before RA diagnosis.
Cardiovascular Disease Risk Persists Years After Treatment of Thyrotoxicosis
Excess cardiovascular disease mortality persisted for many years after thyroid-ablative treatment in patients who received radioactive iodine who did not become hypothyroid.
Risk of Thyroid Dysfunction Not Associated With HIV Status
Compared with uninfected individuals, people with HIV controlled with combination antiretroviral therapy are not at increased risk of developing thyroid dysfunction.
Subclinical Thyroid Dysfunction Not Associated With Hip Fracture Risk in Older Men
Findings do not support a role for subclinical thyroid dysfunction as a biomarker for bone-related outcomes in older men.
Impaired Vascular Dysfunction in Primary Hyperparathyroidism May Impact Cognition
It has been previously reported that parathyroidectomy can reverse cognitive dysfunction associated with primary hyperparathyroidism.
Maternal Thyroid-Stimulating Hormone, Free Thyroxine Associated With BMI
Maternal thyroid function and weight gain in early pregnancy were associated with hypothyroidism, but not hyperthyroidism.
Active Ophthalmopathy Benefits From Teprotumumab Treatment
Patients given teprotumumab were more likely to experience a response at 24 weeks vs placebo.
Next post in Thyroid
